RUX+Steroids: Patients with acute grade II GVHD are treated with a combination of methylprednisolone (0.5 mg/kg/day) and ruxolitinib.
Study summary
This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.
Eligibility
Sex
ALL
Min age
—
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients with malignant hematologic diseases eligible for allogeneic hematopoietic stem cell transplantation, including MDS-RAEB, acute leukemia, and chronic phase of CML.
* Availability of an HLA-matched sibling donor, unrelated donor, or haploidentical donor.
* Age ≥ 14 years.
* Liver function: ALT and AST ≤ 2.5 × upper limit of normal (ULN), total bilirubin ≤ 2 × ULN.
* Renal function: serum creatinine ≤ ULN.
* Absence of uncontrolled infection or severe psychiatric/psychological disorders.
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
* Signed informed consent.
* Diagnosis of grade II acute GVHD as assessed by the modified Glucksberg grading criteria for acute GVHD.
Exclusion Criteria:
* Absence of an allogeneic donor.
* Pregnancy of either the donor or the recipient.
* Presence of psychiatric disorders or other conditions that preclude compliance with the study protocol.
Primary outcome measure(s)
Graft-Versus-Host Disease-Free, Relapse-Free Survival — 1 years after treatment Graft-versus-host disease-free, relapse-free survival (GRFS) refers to the time from the start of treatment (or from transplantation) to the first occurrence of any of the following events: grade III-IV acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD) requiring systemic immunosuppressive therapy, disease relapse or progression, or death from any cause.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.